Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FIRM: mFOLFOX6 and Serplulimab in Locally Advanced Rectal Cancer
NCT06688786Active, not recruiting
- Sponsor
- Xinhua Hospital
- Start
- Nov 2024
- Primary completion
- Jul 2025
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Open-label, single-arm trial of serplulimab in rectal cancer, sponsored by Xinhua Hospital. Primary endpoints: Pathological complete response and Major Pathological Response. Started Nov 2024; status: active, not recruiting.
02
Drugs
serplulimab
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT06688786.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06688786.